strategic overview pmag


The Pharmaceutical manufacturer’s Association of Ghana (PMAG) was founded in 1991 (26years now). Member of WAPMA (West African Pharmaceutical Manufacturer’s Association) and Member of FAPMA (Federation of African Pharmaceutical Manufacturer's Association), Member of AGI (Association of Ghana Industries) Has an Executive Secretary with Executive members Office is located at Trade Fair .


To establish a modern and sustainable pharmaceutical manufacturing Industry in Ghana, which enables people to have equal and early access to the best and safest medicines, which are manufactured locally, ensures the highest security of the medicines supply chain and also contributes significantly to economic growth.


To promote pharmaceutical manufacturing in Ghana, by creating a favorable economic, regulatory and political environment, that enables the pharmaceutical manufacturing industry to meet the growing healthcare needs and expectations of the nation in particular and the international community in general.

                             STRENGTHS                                                                         WEAKNESSES
1. Over a Silver Jubilee in pharmaceutical manufacturing   1. No WHO GMP certified manufacturer
2. Robust and well equipped FDA 2. No Legal framework
3. Ghanaian pharma manufacturers stand for Quality  


                       OPPORTUNITIES                                                                           THREATS
1. 5 WHO GMP certified manufacturers by end of 2018   1. Nigeria has 5 WHO GMP certified manufacturers
2. Global Fund quota 2. Governmental incentives favoring importation
3. Multi national contract manufacturing  
4. ECOWAS market


1. Employment can increase by more than 50% every year. Direct Employment of 4,500 people now and to increase to 9,600 by end of 2018. Includes: Pharmacists, Chemists, Engineers, Quality Assurance Personnels, Procurement Personnels, Human Resource Managers,Administrators, Warehouse Managers, Finance Personnels, Distribution Personnels, Transport Personnels, IT Personnels, Technicians, Cleaners, Messengers, ETC


2. Indirect Employment of 890,000 people and to increase to 1,960,000 by end of 2018.Includes Regulatory Personnels, Doctors (About 2,000 Public and Private Hospitals), Pharmacists (About 3,000 pharmacies), Nurses Dispensing Technicians, Pharmacy Assistants Medical Counter, Assistants Chemical Sellers (13,000 shops), Policy Personnels, Legal Personnels, Securities, Drivers, Caterers, Packaging Specialists, Repairers, Trainers, ETC
3. Healthy Nation of 28.56m people Affordable and Accessible Cash System Public- Government hospitals. Private- Private hospitals. Sustainable and Comprehensive Non Cash Systems Public Insurance- NHIS Private Insurance- Nationwide, Enterprise, GLICO, Acacia, etc
4. Health Tourism Ensure that all the drug and non drug components of Health care delivery are affordable and accessible.
5. Stability of the Cedi Little importation Development of the API to Finished products
6. Attract Investments GLOBAL Fund for HIV/AIDS, Tuberculosis and Malaria- $30.7bm globally and $25m for Africa as at July, 2016
7. Trained Professionals Industry Trained CePAT UNIDO
1. Funding $10-15m for each of the 32 manufacturers with a 2-5 years moratorium and 5% interest rate to be paid over 10 years Investors- Debt or Equity financing Government Support- EXIM Bank (5 manufacturers had $5m from EDAIF Fund), more manufacturers should benefit.
2. Expanded Markets Procurement of 100% of medicines that are locally manufactured and are on the government tender. From 33.3% of public procurement to 80% GLOBAL Fund ECOWAS (Cape Verde, Gambia, Ghana, Liberia, Mali, Nigeria, Sierra Leone) UEMOA members (Benin, Burkina Faso, Guinea, Guinea-Bissau, Ivory Coast, Senegal, Niger and Togo
3. Possible Contribution by Government Legal Framework Strategic tariff barriers- to support local pharmaceutical manufacturers Taxation- true VAT exemption of Raw materials and packaging materials for local pharmaceutical manufacturers.

FDA- Expedited registration of locally manufactured products. FDA- Patent laws on Imported medicines to be reduced from 20 years to 7 years and to consider process patents only Communication Strategy to increase public preference for locally manufactured medicines Marketing Strategy including detailing of HCPs, attractive packaging, etc


4. Long term contracts of up to 5 years awarded and signed contracts for local manufacturers.
5.  50% pre-payment of Awarded tenders
6.Restriction as soon as a medicine is locally manufactured Strategic engagement of the NHIS Board
7. Government to reimburse NHIS accredited facilities who procure locally manufactured pharmaceuticals within 3 months.
8. Biotech Farms with allocated lands of 20 acres per manufacturer in a designated area of 2,000 acres in 5 regions with very cheap utilities and incentives.
9. National Chemical Labs to develop APIs in Collaboration with Noguchi, CSIR, Chemistry labs in all the schools Bioequivalence center
10. Favorable ECOWAS Harmonization- Common External Tariff of 20% on imported medicines and 0% on locally manufactured medicines
11. Preference for all Locally manufactured pharmaceutical products (even if the price is up to 15% more)
12. Quota of 80% of the procured medicines
1. EDAIF Funds that benefited 5 manufacturers
2. Tax Exemption of Raw Materials and Packaging materials that are used Local Pharmaceutical manufacturing.
3. Local Pharmaceutical manufacturers supply 33.33% of the medicinal needs of the country
4. Local Pharmaceutical manufacturers supply 19 of the 20 most used essential medicines on the NHIS List .
5. Restricted Drug List
6. FDA renewal for local pharmaceutical manufacturers has been increased from 3 to 5 years
7. ECOWAS Harmonization
www.worldometers. Info
Pharmacy Council